Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340488 | 0.86 | TSHR (0.58) | LOXL2CYP4F2CYP4A11SLC7A5CASR | |
| SCHEMBL3636710 | 0.85 | TDP1 (0.51) | LOXL2CYP4F2CYP4A11SLC7A5CASR | |
| SCHEMBL2458334 | 0.84 | KMT2A (0.46) | LOXL2CYP4F2CYP4A11CA12CA1 | |
| SCHEMBL14108185 | 0.83 | OPRD1 (0.48) | TSHR | |
| SCHEMBL3340741 | 0.81 | GPR17 (0.50) | LOXL2CYP4F2CYP4A11SLC7A5CASR | |
| SCHEMBL1568650 | 0.79 | ADRB2 (0.54) | LOXL2CYP4F2CYP4A11TSHRPOLB | |
| SCHEMBL5662355 | 0.79 | LOXL2 (0.51) | LOXL2CYP4F2CYP4A11SLC7A5CASR | |
| SCHEMBL4407209 | 0.78 | TSHR (0.53) | LOXL2CYP4F2CYP4A11SLC7A5CASR | |
| SCHEMBL2650423 | 0.78 | TSHR (0.53) | LOXL2CYP4F2CYP4A11SLC7A5CASR | |
| SCHEMBL4407205 | 0.78 | TSHR (0.53) | LOXL2CYP4F2CYP4A11SLC7A5CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414072-B2 | Aryl 5-thio-β-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-19 | — | — | US | disclosed |
| CN-100341885-C | Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides | TAISHO PHARMACEUTICAL CO LTD (JP) | 2007-10-10 | — | — | CN | disclosed |
| US-7250522-B2 | Method for selective preparation of aryl 5-thio-β-D-aldohexopyranosides | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-31 | — | — | US | disclosed |
| CN-1312165-C | Aryl 5-thio-beta-D-glucopyranoside derivative and therapeutic agent for diabetes containing the same | TAISHO PHARMACEUTICAL CO LTD (JP) | 2007-04-25 | — | — | CN | disclosed |
| US-20050256317-A1 | Process for selective production of aryl 5-thio-beta-d- aldohexopyranosides | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| CN-1675233-A | Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-09-28 | — | — | CN | disclosed |
| US-20050209309-A1 | Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-22 | — | — | US | disclosed |
| CN-1639180-A | Aryl 5-thio-beta-D-glucopyranoside derivatives and remedies for diabetes containing the same | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-07-13 | — | — | CN | disclosed |
| EP-1541578-A1 | PROCESS FOR SELECTIVE PRODUCTION OF ARYL 5-THIO-BETA-D-ALDOHEXOPYRANOSIDES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1528066-A1 | ARYL 5-THIO-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256317-A1 | Process for selective production of aryl 5-thio-beta-d- aldohexopyranosides | ALDOA, DERA, AKR1D1 | LOXL2 4042/4885CYP4F2 238/4885CYP4A11 22/4885 |
| US-20050209309-A1 | Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same | SLC5A2, SLC5A1, UGGT1 | LOXL2 2881/4885CYP4F2 568/4885CYP4A11 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.